Top Tweets for #AllostericModulator
A new study developed a method to identify nanobody ligands for GPCRs, yielding selective modulators and inhibitors for AT1R, demonstrating nanobodies' potential for the development of next-generation GPCR therapeutics #AT1R #Nanobody #Allostericmodulator
https://t.co/STAwgJgn4P
conference call and webcast at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) that day to discuss the financial results and provide a business update on our #allostericmodulator pipeline.
https://t.co/04dtL4SdXq
We are proud to announce that @Indivior has selected clinical candidates from our #GABAB positive #allostericmodulator (PAM) research collaboration. Indivior is developing its candidate in substance use disorder and is responsible all future development. As part of the agreement,
Data from studies in models of chronic #cough, which will be presented at the Thirteenth London International Cough Symposium (13th LICS) on July 19, showed that our #GABAB positive #allostericmodulator exhibited robust antitussive efficacy,
Mr. Dyer will be available for meetings throughout the conference. Contact [email protected] if you’re interested in meeting.
#allostericmodulator #SwissBiotechDay #CNS #drugdevelopment
Our CEO, Tim Dyer, will be participating in the virtual @Biotechgate Digital Partnering conference (February 26-March 1). Interested in hearing about Addex’s #allostericmodulator platform and #CNS #drugdiscovery?
in progressive weakness and wasting of muscles. There is no cure. At Addex Therapeutics, we are supporting CMT research and drug discovery through the development of positive #allostericmodulator drugs targeting #GABAB, which we believe could benefit patients with CMT1A,
Excited to lead this consortium in the development of a first-in-class metabotropic glutamate 2 (#mGlu2) receptor negative #allostericmodulator (NAM) for the treatment of mild neurocognitive disorder (#mNCD). We have already made significant progress in developing novel highly
Our CEO, Tim Dyer, is attending #BioEquity Europe in Dublin. Get in touch if you’re interested in catching up during the meeting to discuss our #allostericmodulator drug discovery & development ([email protected]).
ADX71149 is our selective metabotropic glutamate sub-type 2 (mGlu2) receptor positive #allostericmodulator (PAM).
beneficial effects on non-motor symptoms (NMS) experienced by #Parkinson’s patients in addition to its established positive effects on #dyskinesias. Dipraglurant is an mGlu5 negative #allostericmodulator (NAM) that has successfully completed a
We are happy to announce that we have closed the previously disclosed $5 million #financing. The net proceeds will be used to advance our portfolio of #allostericmodulator drug candidates and provide cash runway through Q2 2024. #drugdevelopment
https://t.co/siZ1v63bQV
Today, we announced data published in Cells showing that #dipraglurant could have beneficial effects on non-motor symptoms experienced by #Parkinson’s patients, in addition to its established positive effects on dyskinesias. Dipraglurant is an #mGlu5 negative #allostericmodulator
Today, we announced a definitive agreement to raise approximately $5 million. The net proceeds will be used to advance our portfolio of #allostericmodulator drug candidates and for general corporate purposes.
and @rlutjens Robert Lütjens, Head of Discovery – Biology, will deliver a presentation followed by a Q&A session on the results and progress being with our #allostericmodulator pipeline in more detail.
https://t.co/R4xwVR72cm
the same day to discuss the results and progress with our #allostericmodulator pipeline in more detail.
https://t.co/1xJt96Eqkq
selective metabotropic #glutamate type 2 (mGlu2) receptor positive #allostericmodulator (PAM), is currently in clinical development. #EpilepsyDay
positive #allostericmodulator (PAM). Data from Part 1 will now be evaluated by an independent interim review committee (IRC), the results of which will be reviewed by Janssen to evaluate next steps for the program. Results of the review are expected at the end of Q1 2023.
Interested in meeting to discuss our #allostericmodulator drug pipeline and technology platform? Contact us via the partnering system or [email protected]. #drugdiscovery #drugdevelopment #CNS
Addex will use the net proceeds from this offering to advance its clinical and preclinical #allostericmodulator pipeline. #equityfinancing #drugdevelopment
https://t.co/OXfGXgxVpa
Last Seen Hashtags on Sotwe
bakırköygay
Seen from Turkey
minichat
Seen from United States
boluaktif
Seen from Turkey
mother incest
Seen from Italy
minichat filter:videos
Seen from Switzerland
DJezROCK
Seen from United States
teenageee
Seen from United States
媚黑
Seen from United States
mgai()()() + filter:native_video
Seen from Algeria
minichat #teenageee
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
83.9M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers